Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment ...

Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

If Sanofi opts in to the other project, Regeneron will lead MUC16xCD3 bispecific development and marketing in the US. The companies will share development costs and profits.

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in ... added to background maximal standard-of-care inhaled therapy in adults with uncontrolled COPD ...